Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
63%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(2)
Other(5)

Detailed Status

unknown5
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

active_not_recruiting113%
completed225%
unknown563%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05426486
unknownphase_2

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

NCT05328440
unknownphase_2

Phase II Umbrella Study Directed by Next Generation Sequencing

NCT03574402
completedphase_1

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate

NCT04315116
unknown

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

NCT05411276
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05426486Phase 2

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Active Not Recruiting
NCT05328440Phase 2

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Unknown
NCT03574402Phase 2

Phase II Umbrella Study Directed by Next Generation Sequencing

Unknown
NCT04315116Phase 1

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate

Completed
NCT05411276

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Unknown
NCT04903652Phase 2

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Completed
NCT05274191Phase 2

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Unknown
NCT04680091Phase 1

Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8